Mira Tadros, DO
Sleep Medicine · New York, NYNPI 1467984864
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $404 of the $518 with a category attached, or 78.1%. 8 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 29.4% of the total. Reporting peaked in 2022 at $305 and has fallen 64.4% since, to $109 in 2023. That places this record below the midpoint for sleep medicine clinicians in NY, where the typical reported total is $1,050.
Across 21 payments — averaging $24.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$152
- Boehringer Ingelheim$142
- Harmony Biosciences LLC$95
- Resmed Corp$33
- Inspire Medical Systems, Inc.$31
- Axsome Therapeutics, Inc.$27
- plus $37 from 2 others
What the payments were for
- Consulting fees$184%
- Food & beverage$40478%
- Education$9518%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 6 | $152 |
| Boehringer Ingelheim | 9 | $142 |
| Harmony Biosciences LLC | 1 | $95 |
| Resmed Corp | 1 | $33 |
| Inspire Medical Systems, Inc. | 1 | $31 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Baxter Healthcare | 1 | $19 |
| Itamar Medical Inc | 1 | $18 |
How this compares
$518 in reported general payments places this provider in the 40th percentile of 81 sleep medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelsomraSuvorexant | 19 | $8,497 |
| Zolpidem Tartrate | 19 | $16 |
Paid to pharmacies, not to this prescriber.
Other sleep medicine in New York
- David RapoportNew York$313K
- Ofer JacobowitzNew York$141K
- Andrew WestwoodNew York$82K
- Omar BurschtinNew York$71K
- Maha AhmadNew York$38K
- Daniel BaroneNew York$37K
- Vincent GrbachNew York$21K
- Andrew VargaNew York$19K
- Courtney ChouNew York$16K
- Klaus Dieter LessnauNew York$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.